In advanced prostate cancer and castrate-resistant disease state, a class of mutations in the androgen receptor has been identified with a complete loss of the ligand binding domain and functionally constitutively active without any need for androgen ligands [180]. The gene discussed is AR; the disease is prostate carcinoma.